If you would like to be considered for a clinical trial you will require a referral from your current treating team. Visit the Joining a clinical trial page for referral information.
For more information on neurological cancer trials, get in contact with our Monc A team This email address is being protected from spambots. You need JavaScript enabled to view it..
Open and Recruiting Clinical Trials
AB-218-G203 / SIGMA
A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1)-mutant glioma
Trial ID
NCT05303519
Cancer type
Glioma
Status
Open to recruitment
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
PRIME / CA240-0032
A Phase 0/II open-label study of perioperative PRMT5 Inhibition with BMS-986504 in patients with recurrent MTAP-deleted glioblastoma
Trial ID
ACTRN12625001238460
Cancer type
Glioma
Status
Open to recruitment
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
IVY-P3-24-021
A Phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma
Trial ID
NCT06388733
Cancer type
MGMT unmethylated glioblastoma
Status
Open to recruitment
Phase
Phase three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to existing treatments available for that cancer type
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
PAS-004-103
A Phase 1/2 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PAS-004, a Protein Kinase (MEK) 1+2 Inhibitor, in adult patients with Neurofibromatosis Type and cutaneous NF-1
Trial ID
NCT06961565
Cancer type
Neurofibromatosis type and cutaneous NF-1
Status
Open to recruitment
Phase
Phase one / two: A phase one / two clinical trial combines a phase one and two. The phase one tests new treatments sometimes for the first time in humans, usually in a small group of patients. The phase two-part tests the new treatment in a larger group of patients with selected cancer types. The aim of a phase one / two is to find the best dose of the new treatment and see if it works against the cancer
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
BrainPOP Precision
Evaluating the feasibility and impact of the implementation of precision medicine into the care of patients with brain cancers
Trial ID
ACTRN12624000884505
Cancer type
Brain cancers (central nervous system cancer, glioblastoma)
Status
Open and recruiting
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Cancer Clinical Trial Registry.
GCAR-7213 / GBM AGILE
Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Trial ID
NCT03970447
Cancer type
Glioblastoma
Status
Open and recruiting
Phase
Phase two / three: A phase two / three clinical trial follows a phase one / two, in a larger group of patients with specific cancer types. The aim of a phase two / three is to compare the new treatment to existing treatments available for that cancer type and closely monitor patients to make sure the treatment is safe and effective in that cancer type.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
COGNO2201 / LUMOS2
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Trial ID
ACTRN12623000096651
Cancer type
Glioma
Status
Open and recruiting
Phase
Phase Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your doctor if you are interested in this clinical trial.
For full inclusion / exclusion criteria refer to the Australian Clinical Trials Registry.
If you don’t find what you are looking for or would like a center closer to home that may also provide similar clinical trials, refer to the Victorian Cancer Trials Link or Australian Clinical Trials Registry.
